HLA-E and myeloid sarcoma: With different factors displaying complex interplay, multiple factors combined were further analyzed and among them EBV LMP1 variant (GGDPHLPTL and GGDPPLPTL) plus HLA-E*0101 allele together were found associated with a 261.3-fold (OR with 95% CI, 261.3 95% CI 15.8–431.0) increase in the risk of developing MS for people with high EBNA386–405-specific antibody level.